External validity of clinical trials with diverse trastuzumab-based chemotherapy regimens in advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry.

Paula Jiménez-Fonseca,Alberto Carmona-Bayonas,Alba Martínez-Torrón,Maria Alsina,Ana Custodio,Olbia Serra,Diego Cacho Lavin,Maria Luisa Limón,Tamara Sauri,Flora López,Laura Visa,Mónica Granja,Nieves Martínez Lago,Virginia Arrazubi,Rosario Vidal Tocino,Raquel Hernández,Gema Aguado,Juana María Cano,Alfonso Martin-Carnicero,Monserrat Mangas,Paola Pimentel,Ana Montes,Ismael Macias Declara,Federico Longo,Avinash Ramchandani,Marta Martin-Richard,Alicia Navajas Hurtado,Aitor Azkarate,Carolina Hernandez-Perez,Raquel Serrano,Javier Gallego

External validity of clinical trials with diverse trastuzumab-based chemotherapy regimens in advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry.

2021

Background:Trastuzumab combined with cisplatin and fluoropyrimidines, either capecitabine or 5-fluorouracile (XP/FP), is the standard first-line treatment for advanced, HER2-positive, gastric cance...

Keywords:

Clinical trial
gastroesophageal adenocarcinoma
Internal medicine
Oxaliplatin
Medicine
Capecitabine
Trastuzumab
Oncology
Chemotherapy
External validity
Cisplatin

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations